Selective serotonin receptor inverse agonists as therapeutics for disease

• US 20050261340A1
• Filed: 05/21/2004
• Published: 11/24/2005
• Est. Priority Date: 05/21/2004
• Status: Active Grant

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Davis, Robert E., Brann, Mark R., Weiner, David M.
• Granted Patent: US 7,820,695 B2
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.

Claims

1. A pharmaceutical composition comprising a compound of Formula (I)

2. The pharmaceutical composition of claim 1, further comprising physiologically acceptable carrier, diluent, or excipient, or a combination thereof.

3. A method of treating depression in a patient comprising:

identifying a patient in need thereof, and

administering to said patient a therapeutically effective amount of a compound of Formula (I)

in combination with a therapeutically effective amount of fluoxetine.